Result of AGM

RNS Number : 5117M
Oxford Biomedica PLC
07 May 2015
 

 

 

 

 

 

 

Oxford BioMedica Annual General Meeting

 

London, UK - 7 May 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

In accordance with Listing Rule 9.6.18 the following resolutions are those which were passed at the meeting concerning special business:

 

·      Resolution 14: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Companies Act 2006 as if section 561 of the Companies Act 2006 did not apply to such allotment, up to an aggregate nominal amount of 5 per cent. of the presently issued shares; and

 

·      Resolution 15: to permit the Group to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

 

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting the Group's website at www.oxfordbiomedica.co.uk.

 

Certified copies of the document setting out the above resolutions passed at the 2015 AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at: http://www.morningstar.co.uk/uk/NSM.

 

The results of the proxy voting in advance of the meeting are shown below.  On the Record Date (5 May 2015) there were 2,568,040,015 1p ordinary shares in issue, each carrying one vote per share.

 

 

 

Resolution

 

Votes

For

Votes at

Chairman's

Discretion

Votes at

other proxy

Discretion

 

Votes

Against

 

Votes

Withheld

 

Total

votes cast

Result









Ordinary resolutions














1

1,569,855,529

997,910

3,429,924

44,395

37,743

1,574,365,501

Passed









2

1,568,499,344

1,124,976

3,429,924

1,144,667

166,590

1,574,365,501

Passed









3

1,559,509,773

1,151,115

3,429,924

2,231,914

8,042,775

1,574,365,501

Passed

4

  1,565,366,633

 

998,823

 

3,429,924

 

4,512,371

 

45,191

 

1,574,352,942

 

Passed









5

1,565,363,916

998,823

3,429,924

4,513,033

47,246

1,574,352,942

Passed









6

1,565,365,962

998,823

3,429,924

4,503,033

55,200

1,574,352,942

Passed









7

1,565,355,486

996,203

3,429,924

4,512,371

58,958

1,574,352,942

Passed









8

1,569,730,217

1,000,773

3,429,924

116,408

88,179

1,574,365,501

Passed









9

1,559,704,929

1,052,832

3,429,924

2,148,027

8,029,789

1,574,365,501

Passed









10

1,561,084,685

1,108,626

3,429,924

846,210

7,896,056

1,574,365,501

Passed









11

1,561,001,842

1,068,751

3,429,924

966,478

7,898,506

1,574,365,501

Passed









12

  1,569,491,544

 

1,060,845

 

3,429,924

 

190,709

 

192,479

 

1,574,365,501

 

Passed









13

1,569,481,603

1,057,412

3,429,924

249,740

146,822

1,574,365,501

Passed









 

Special resolutions














14

1,568,482,462

1,155,736

3,429,924

1,090,080

207,299

1,574,365,501

Passed









15

1,566,284,325

1,208,555

3,429,924

3,313,737

128,960

1,574,365,501

Passed









 

The following resolution was taken on a poll called by the Chairman of the Company at the meeting:

 

·      Resolution 15: to permit the Group to convene general meetings (other than annual general meetings) on not less than 14 days' notice.

 

The results of the votes cast were as follows:

 

Votes For

Votes Against

Votes Withheld

Total Votes Cast

Result

1,583,347,994

6,562,802

7,731,340

1,589,910,796

Passed

 

The number of votes validly cast in relation to Resolution 15 was 1,589,910,796, which constitutes 61.91% of the issued share capital of the Company.

 

- Ends -

 

For further information, please contact:

 

 

Oxford BioMedica plc:

John Dawson, Chief Executive Officer

Tim Watts, Chief Financial Officer

 

Tel: +44 (0)1865 783 000

 

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton

 

 

 

Tel: +44 (0)20 3709 5700

Notes for editors

 

About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk .

 


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

RAGSSUFFWFISEII